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ABSTRACT
McCune-Albright syndrome (MAS) is one of the conditions causing precocious gonadotropin-independent puberty. It is a rare disease, 
characterized by two of the three following features: precocious puberty, polyostotic fibrous dysplasia (PFD), and café au lait (CAL) skin spots. 
Herein is presented the case of a girl with pubarche, acne, and transient thelarche since the age of three and menarche since the age of 
six years old. Besides transitory follicular cysts and advanced bone age, no other changes were found. Diagnosis was only established after 
brain magnetic resonance imaging showed fibrous dysplasia involving left craniofacial bones. The girl’s parents later mentioned that she had 
multiple café au lait skin spots on the scalp since birth, disclosing how the key diagnostic sign had been covered by the child’s hair. 
MAS is a rare disorder and diagnosis depends on a high index of suspicion. CAL skin spots are generally the first manifestation, but can easily 
go unnoticed. Additionally, PFD may only affect some bones, like craniofacial.
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RESUMO
A puberdade precoce periférica pode ter várias etiologias, entre as quais a síndrome McCune-Albright (SMA). Trata-se de uma doença rara, 
definida por um mínimo de dois de três critérios clínicos: puberdade precoce, displasia fibrosa poliostótica (DFP) e manchas café-au-lait  (CAL). 
Apresenta-se o caso de uma criança do sexo feminino com pubarca, acne e telarca intermitente desde os três anos de idade e menarca desde 
os seis. Dos exames complementares destacavam-se apenas alguns quistos foliculares transitórios e um avanço de idade óssea. O diagnóstico 
foi possível por ressonância magnética crânio-encefálica, que evidenciou a existência de DFP envolvendo os ossos do crânio e hemiface 
esquerda. Apenas mais tarde foi referido pelos pais que a criança tinha múltiplas manchas CAL no couro cabeludo desde o nascimento, 
evidenciando como neste caso a chave para o diagnóstico se encontrava escondida pelo cabelo.
A SMA é uma doença rara cujo diagnóstico depende de um elevado índice de suspeição. As manchas CAL geralmente são as primeiras 
manifestações, mas podem facilmente passar despercebidas. A DFP pode afetar apenas alguns ossos, como os craniofaciais. 
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CASE REPORT
A three-year-old girl was referred to our Pediatric Endocrinology 
Unit due to pubic hair growth since the age of 30 months. On 
clinical examination, she was on the 75th weight and 50th height 
percentile (according to WHO criteria), Tanner stage A1/P2/B1, and 
had two hyperpigmented skin lesions (6x10 cm on the back; 2x5 
cm in the neck). No other findings were noticed. Laboratory study 
indicated elevated S-DHEA (192 μg/dL), normal total testosterone 
(13.9 ng/dL), normal TSH/FT4 (2.11 μU/mL; 0.93 ng/dL), and normal 
cortisol (9.1 μg/dL), IGF-1 (102 ng/mL), and prolactin (5.2 ng/mL). 
Adrenocorticotropic hormone (ACTH) test was normal and basal 
luteinizing hormone (LH), follicle-stimulating hormone (FSH), and 
estradiol levels were also normal (2.72 U/L; <0.07 U/L; <19.0 pg/mL). 
At the age of four, the child had facial acne, more pubic hair (Tanner 
P3), and advanced bone age of more than two years. Six months 
later, bilateral mammary gland was palpable (Tanner B2P3), although 
intermittently with posterior regression, and pelvic ultrasound 
revealed a 27-mm simple cyst on the right ovary and a 6.2-mm cyst 
on the left ovary. A few days later, gonadotropin-releasing hormone 
(GnRH) stimulation test was performed, but LH, FSH, and estradiol 
were on pre-pubertal levels. One year later, the girl had grown 
over 8 cm/year (>97th percentile of height velocity) and mammary 
gland was again not palpable (Tanner A2/P3/B1). First menstrual 
bleeding appeared almost two years later when the girl was six years 
and three months old. Subsequently, GnRH test showed elevated 
estradiol with low LH/FSH, compatible with peripheral precocious 
puberty. Despite this, considering the dramatic puberty evolution 
and to completely rule out a central precocious puberty cause, brain 
magnetic resonance imaging (MRI) was conducted, revealing signs 
of polyostotic fibrous dysplasia of the skull base and left temporal, 
parietal, and facial bones. Diagnosis of McCune Albright syndrome 
(MAS) presenting with precocious puberty and polyostotic fibrous 
dysplasia was considered at this point. Only later did the parents 
mention multiple scalp lesions (corresponding to café au lait [CAL] 
skin spots) present on the girl’s scalp since birth and not easily visible.
A luteinizing hormone-releasing hormone (LHRH) analog was 
initiated (monthly, via intramuscular administration) to suppress the 
secondary central precocious puberty that ultimately occurred.
Child’s wellbeing currently remains unaltered. She is on the 75th 
height percentile, has no additional organ involvement, and attends 
follow-up consultations twice a year.  
DISCUSSION
MAS is a rare sporadic disease with an estimated prevalence between 
1/100,000 and 1/1,000.000.1 It is caused by a missense somatic 
mutation in the α-subunit-encoding gene of G-protein, leading to 
activation of several hormonal receptors, as ACTH, TSH, FSH, and 
LH. It is acknowledged as a postzygotic mutation and therefore 
1 A) 1 B) 1 C)
Figure 1(A-C) -  Brain MRI showing polyostotic fibrous dysplasia features involving the skull base and occipital, left temporal, and left parietal 
bones. Low sphenoid and left maxillary sinuses permeability were also evident
each patient presents somatic mosaicism.2 By definition, MAS is 
characterized by two of three clinical features: precocious puberty, 
polyostotic fibrous dysplasia, and café au lait skin spots. However, 
since virtually every gland or tissue can be affected, several clinical 
phenotypes are possible. Although precocious puberty is by far the 
most frequent, other hyperfunctional autonomous endocrinopathies 
may also be present: hyperthyroidism, Cushing’s syndrome, growth 
hormone (GH) excess, and renal phosphate wasting with or without 
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rickets/osteomalacia. Other organs may also be involved, as the 
liver, heart, pancreas, or those of the gastrointestinal system, but 
represent less common features.3,4 It should be noticed that most 
clinical signs are present on first examination and generally persist 
throughout life (except for Cushing’s syndrome, phosphaturia, and 
precocious puberty). It is therefore crucial to be aware of all possible 
manifestations to make a diagnosis.4
Diagnosis is usually established based on clinical manifestations, 
but several laboratory and imaging tests may be useful. Skeletal 
radiograph may evidence the “ground glass” appearance of PFD 
bones; pelvic ultrasound may reveal cyst or ovary enlargement; 
biochemical findings may disclose high estradiol and low FSH/LH levels 
(compatible with peripheral precocious puberty) or other alterations 
(TSH/T4, GH, cortisol), depending on which endocrinopathy occurs.2 
Other precocious puberty causes (such as congenital adrenal 
hyperplasia, brain lesions, ovarian tumors) and CAL skin spots 
(neurofibromatosis type 1) should be considered in the differential 
diagnosis. 
Since there is no specific MAS treatment, therapeutic measures 
are directed at (developing) signs and symptoms. In the present 
case, precocious puberty was pharmacologically treated due to 
the potential psychological and final stature consequences. Data 
regarding the use of bisphosphonates − primarily used for bone pain 
reduction − in PFD is conflicting.5,6 Nonetheless, this patient did not 
present such symptom.
Although MAS is generally not associated with increased mortality 
and morbidity, several factors should be assessed: (i) which (and 
when) endocrine disorders arise, (ii) other solid organ involvement, 
presence of (iii) fractures or (iv) malignancies, among others. Being 
a multisystemic condition, disease management is challenging and 
should be conducted in a specialized center.5
CONCLUSION
This was a challenging case, as most diagnostic clues were hidden 
by the patient’s hair. Initial evaluation was based on common 
precocious puberty causes, but transient physical signs (telarche and 
ovarian cysts) plus normal hormone levels and absence of other signs 
hampered their interpretation. 
Take-home messages:
• Although rare, MAS should always be considered a precocious 
puberty etiology.
• CAL skin pigmentation should raise clinical suspicion of MAS.
• MAS diagnosis is challenging and may require careful full body 
examination and several endocrine tests.
• There is no cure for MAS and treatment options vary according 
to clinical manifestations. Treatment goal (whether medical or 
surgical) is to relieve symptoms and offset physical shortcomings, 
ensuring the best possible quality of life.
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